BridgeBio Oncology Therapeutics, Inc. (BBOT) — insider trading
Health Care · NASDAQ
BridgeBio Oncology Therapeutics, Inc. (BBOT) has 27 reported SEC Form 4 insider transactions in our data (latest 2026-10-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Cobo Marc | Officer (Principal Accounting Officer) | Shares withheld for taxes / exercise cost | 126 | $3.94 | $496 | Form 4 |
| 2026-10-01 | Elmelech Idan | Officer (COO & Principal Financial Ofcr) | Shares withheld for taxes / exercise cost | 343 | $3.94 | $1.4K | Form 4 |
| 2026-10-01 | Ben Yong | Officer (Chief Med & Dev Officer) | Shares withheld for taxes / exercise cost | 1,047 | $3.94 | $4.1K | Form 4 |
| 2026-10-01 | Beltran Pedro | Director, Officer (President and CEO) | Shares withheld for taxes / exercise cost | 1,047 | $3.94 | $4.1K | Form 4 |
| 2026-09-10 | Cobo Marc | Officer (Principal Accounting Officer) | Grant / award / vesting (derivative) | 43,700 | — | $0 | Form 4 |
| 2026-09-10 | Cobo Marc | Officer (Principal Accounting Officer) | Shares withheld for taxes / exercise cost | 203 | $5.52 | $1.1K | Form 4 |
| 2026-09-10 | Cobo Marc | Officer (Principal Accounting Officer) | Grant / award / vesting | 9,038 | — | $0 | Form 4 |
| 2026-07-01 | Chen Bihua | Director, 10% owner | Other acquisition or disposition | 130,865 | — | $0 | Form 4 |
| 2026-07-01 | Chen Bihua | Director, 10% owner | Other acquisition or disposition | 1,704,862 | — | $0 | Form 4 |
| 2026-07-01 | Chen Bihua | Director, 10% owner | Other acquisition or disposition | 2,692,459 | — | $0 | Form 4 |
| 2026-07-01 | Chen Bihua | Director, 10% owner | Other acquisition or disposition | 4,528,186 | — | $0 | Form 4 |
| 2026-07-01 | Beltran Pedro | Director, Officer (President and CEO) | Shares withheld for taxes / exercise cost | 1,047 | $7.80 | $8.2K | Form 4 |
| 2026-07-01 | Ben Yong | Officer (Chief Med & Dev Officer) | Shares withheld for taxes / exercise cost | 1,047 | $7.80 | $8.2K | Form 4 |
| 2026-07-01 | Elmelech Idan | Officer (COO & Principal Financial Ofcr) | Shares withheld for taxes / exercise cost | 343 | $7.80 | $2.7K | Form 4 |
| 2026-07-01 | Cobo Marc | Officer (Principal Accounting Officer) | Shares withheld for taxes / exercise cost | 125 | $7.80 | $975 | Form 4 |
| 2026-06-16 | Kumar Neil | Director | Grant / award / vesting (derivative) | 31,675 | — | $0 | Form 4 |
| 2026-06-16 | Bauer Jake | Director | Grant / award / vesting (derivative) | 31,675 | — | $0 | Form 4 |
| 2026-06-16 | Chen Bihua | Director, 10% owner | Grant / award / vesting (derivative) | 31,675 | — | $0 | Form 4 |
| 2026-06-16 | Kelleher Raymond J. | Director | Grant / award / vesting (derivative) | 31,675 | — | $0 | Form 4 |
| 2026-06-16 | Lebowitz Peter F | Director | Grant / award / vesting (derivative) | 7,289 | — | $0 | Form 4 |
| 2026-06-16 | MCCORMICK FRANK | Director | Grant / award / vesting (derivative) | 31,675 | — | $0 | Form 4 |
| 2026-06-16 | Tipirneni Praveen P. | Director | Grant / award / vesting (derivative) | 31,675 | — | $0 | Form 4 |
| 2026-05-10 | Beltran Pedro | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 1,103,837 | — | $0 | Form 4 |
| 2026-05-10 | Elmelech Idan | Officer (COO & Principal Financial Ofcr) | Grant / award / vesting (derivative) | 758,222 | — | $0 | Form 4 |
| 2026-04-01 | Mehra Uneek | Other | Shares withheld for taxes / exercise cost | 524 | $9.03 | $4.7K | Form 4 |
| 2026-04-01 | Beltran Pedro | Director, Officer (President and CEO) | Shares withheld for taxes / exercise cost | 1,047 | $9.03 | $9.5K | Form 4 |
| 2026-04-01 | Ben Yong | Officer (Chief Med & Dev Officer) | Shares withheld for taxes / exercise cost | 1,047 | $9.03 | $9.5K | Form 4 |
Ask the chat about BBOT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: BridgeBio Oncology Therapeutics, Inc. (BBOT).
Last updated 2026-10-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.